NCT04384393View on ClinicalTrials.gov

Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 9, 2020

Primary Completion Date

November 10, 2022

Study Completion Date

October 24, 2023

Conditions
B Cell Malignancy
Interventions
BIOLOGICAL

ThisCART19 cells

0.2-60 x 10\^6 CAR T cells per kg body weight.

Trial Locations (2)

Unknown

RECRUITING

The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei

RECRUITING

Fundamenta Therapeutice Co.,Ltd, Suzhou

Sponsors
All Listed Sponsors
collaborator

Anhui Provincial Hospital

OTHER_GOV

lead

Fundamenta Therapeutics, Ltd.

INDUSTRY

NCT04384393 - Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies | Biotech Hunter | Biotech Hunter